569 related articles for article (PubMed ID: 12692621)
41. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
42. Factors influencing haemopoietic recovery following chemotherapy-mobilised autologous peripheral blood progenitor cell transplantation for haematological malignancies: a retrospective analysis of a 10-year single institution experience.
Lowenthal RM; Fabères C; Marit G; Boiron JM; Cony-Makhoul P; Pigneux A; Agape P; Vezon G; Bouzgarou R; Dazey B; Fizet D; Bernard P; Lacombe F; Reiffers J
Bone Marrow Transplant; 1998 Oct; 22(8):763-70. PubMed ID: 9827973
[TBL] [Abstract][Full Text] [Related]
43. [Clinical analysis of the fatal cases of adult malignant gliomas after aggressive treatment].
Takamura Y; Ibayashi Y; Morimoto S; Tanabe S; Hashi K
No Shinkei Geka; 1994 Mar; 22(3):207-13. PubMed ID: 8133960
[TBL] [Abstract][Full Text] [Related]
44. Radiotherapy for high-grade gliomas. Does altered fractionation improve the outcome?
Nieder C; Andratschke N; Wiedenmann N; Busch R; Grosu AL; Molls M
Strahlenther Onkol; 2004 Jul; 180(7):401-7. PubMed ID: 15241527
[TBL] [Abstract][Full Text] [Related]
45. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy.
Mizoe JE; Tsujii H; Hasegawa A; Yanagi T; Takagi R; Kamada T; Tsuji H; Takakura K;
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):390-6. PubMed ID: 17459607
[TBL] [Abstract][Full Text] [Related]
46. [Malignant brain glioma--a catamnestic study of 100 operated patients].
Victor S; Lausberg G
Zentralbl Neurochir; 1991; 52(2):59-68. PubMed ID: 1659065
[TBL] [Abstract][Full Text] [Related]
47. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis.
Abrey LE; Moskowitz CH; Mason WP; Crump M; Stewart D; Forsyth P; Paleologos N; Correa DD; Anderson ND; Caron D; Zelenetz A; Nimer SD; DeAngelis LM
J Clin Oncol; 2003 Nov; 21(22):4151-6. PubMed ID: 14615443
[TBL] [Abstract][Full Text] [Related]
48. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
[TBL] [Abstract][Full Text] [Related]
49. Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR.
Snowden JA; Passweg J; Moore JJ; Milliken S; Cannell P; Van Laar J; Verburg R; Szer J; Taylor K; Joske D; Rule S; Bingham SJ; Emery P; Burt RK; Lowenthal RM; Durez P; McKendry RJ; Pavletic SZ; Espigado I; Jantunen E; Kashyap A; Rabusin M; Brooks P; Bredeson C; Tyndall A
J Rheumatol; 2004 Mar; 31(3):482-8. PubMed ID: 14994391
[TBL] [Abstract][Full Text] [Related]
50. The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine.
Selker RG; Shapiro WR; Burger P; Blackwood MS; Arena VC; Gilder JC; Malkin MG; Mealey JJ; Neal JH; Olson J; Robertson JT; Barnett GH; Bloomfield S; Albright R; Hochberg FH; Hiesiger E; Green S;
Neurosurgery; 2002 Aug; 51(2):343-55; discussion 355-7. PubMed ID: 12182772
[TBL] [Abstract][Full Text] [Related]
51. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
52. Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394.
Grossman SA; O'Neill A; Grunnet M; Mehta M; Pearlman JL; Wagner H; Gilbert M; Newton HB; Hellman R;
J Clin Oncol; 2003 Apr; 21(8):1485-91. PubMed ID: 12697871
[TBL] [Abstract][Full Text] [Related]
53. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
[TBL] [Abstract][Full Text] [Related]
54. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
55. [Clinical results of supratentorial astrocytoma grade II].
Matsumoto K; Abe T; Terada K; Tabuchi A; Adachi Y; Mizumatsu S; Ono Y; Tamiya T; Ohmoto T; Furuta T
No Shinkei Geka; 1999 Feb; 27(2):139-45. PubMed ID: 10065446
[TBL] [Abstract][Full Text] [Related]
56. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
[TBL] [Abstract][Full Text] [Related]
57. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
[TBL] [Abstract][Full Text] [Related]
58. Safety and efficacy of high-dose chemotherapy with autologous stem cell transplantation for patients with malignant astrocytomas.
Chen B; Ahmed T; Mannancheril A; Gruber M; Benzil DL
Cancer; 2004 May; 100(10):2201-7. PubMed ID: 15139065
[TBL] [Abstract][Full Text] [Related]
59. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
60. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma.
Benekli M; Smiley SL; Younis T; Czuczman MS; Hernandez-Ilizaliturri F; Bambach B; Battiwalla M; Padmanabhan S; McCarthy PL; Hahn T
Bone Marrow Transplant; 2008 Apr; 41(7):613-9. PubMed ID: 18071290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
